S&P TSX Capped Composite...

US Dollar vs CAD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

XLO Xilio Therapeutics Inc

0.9555

-0.0145 (-1.49%)

Dec 31 2024 - Closed

Delayed by 15 minutes

Form 3 - Initial statement of beneficial ownership of securities

Xilio Therapeutics (NASDAQ:XLO)
Historical Stock Chart
From Dec 2024 to Jan 2025

Click Here for more Xilio Therapeutics Charts.

Xilio Therapeutics (NASDAQ:XLO)
Historical Stock Chart
From Jan 2024 to Jan 2025

Click Here for more Xilio Therapeutics Charts.

Xilio Therapeutics Inc News

Form 8-K - Current report
Thursday 19 December 2024 (2 weeks ago) • Edgar (US Regulatory)

Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI
Thursday 19 December 2024 (2 weeks ago) • GlobeNewswire Inc.

Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer
Monday 16 December 2024 (2 weeks ago) • GlobeNewswire Inc.

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tuesday 3 December 2024 (4 weeks ago) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Thursday 7 November 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 7 November 2024 (2 months ago) • Edgar (US Regulatory)

Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors
Thursday 7 November 2024 (2 months ago) • GlobeNewswire Inc.

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results
Thursday 7 November 2024 (2 months ago) • GlobeNewswire Inc.

Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Wednesday 30 October 2024 (2 months ago) • GlobeNewswire Inc.

Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Friday 4 October 2024 (3 months ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 2 October 2024 (3 months ago) • Edgar (US Regulatory)

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Wednesday 2 October 2024 (3 months ago) • GlobeNewswire Inc.

More Xilio Therapeutics Inc News Articles

Moon Equity (PK)

Anavex Life Sciences

Accredited Solutions (PK)

Digital Brand Media and ... (PK)

Kraig Biocraft Laborator... (QB)

Lightwave Logic

North Bay Resources (PK)

Fannie Mae (QB)

Code Green Apparel (PK)

Intergrated Cannabis Sol... (PK)

Elite Pharmaceuticals (QB)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions